Uterine papillary serous carcinoma evolves via a p53-driven pathway

Human Pathology

Volumn 27, Issue 12, 1996, Pages 1295-1300

  Moll, Ute M ^a,b   Chalas, Eva ^a   Auguste, Madeleine ^a   Meaney, Dana ^a   Chumas, John ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

ovary; p53; peritoneum; serous papillary uterine carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PROGNOSIS; PSAMMOMA BODY; RECURRENCE RISK; STATISTICAL ANALYSIS; SURVIVAL RATE; UTERUS CANCER;

EID: 0029829531     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90340-8     Document Type: Article

References (47)

1. Hendrickson M, Ross J, Eifel P, et al: Uterine papillary serous cacinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6:93-108, 1982
2. Ambros RA, Sherman ME, Zahn CM, et al: Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. HUM PATHOL 26:126-1267, 1995
3. Spiegel GW: Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 19:417-432, 1995
4. Goff BA, Kato D, Schmidt RA, et al: Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 54:264-268, 1994
5. Sherman ME, Bitterman P, Rosenshein NB, et al: Uterine serous carcinoma: A morphologically distinctive neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16:600-610, 1992
6. Kato DT, Ferry JA, Goodman A, et al: Uterine papillary serous carcinoma (UPSC): A clinicopathological study of 30 cases. Gynecol Oncol 59:384-389, 1995
7. Gitsch G, Friedlander ML, Wain GV, et al: Uterine papillary serous carcinoma: A clinical study. Cancer 75:2239-2243, 1995
8. Carcangiu ML, Chamber JT: Uterine papillary serous carcinoma: A study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47:298-305, 1992
9. Silva EG, Jenkins R: Serous carcinoma in endometrial polyps. Mod Pathol 13:120-128, 1990
10. Carcangiu ML, Chambers JT, Voynick IM, et al: Immunohis-tochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. I. Clinical and histological correlations. Am J Clin Pathol 94:247-254, 1990
11. Umpierre SA, Burke TW, Tornos C, et al: Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 13:127-130, 1994
12. Khalifa MA, Mannel RS, Haraway SD, et al: Expression of EGFR, HER-2/neu, p53 and PCNA in endometrioid, serous papillary and clear endometrial adenocarcinoma. Gynecol Oncol 53:84-92, 1994
13. Reinartz JJ, George E, Undgren BR, et al: Expression of p53, transforming growth factor alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. HUM PATHOL 25:1075-1083, 1994
14. Prat J, Oliva E, Lerma E, et al: Uterine papillary serous carcinoma: A 10 cases study of p53 and c-erbB2 expression and DNA content. Cancer 74:1778-1783, 1994
15. Fujino T, Risinger JL, Collins K, et al: Allelotype of endometrial carcinoma. Cancer Res 54:4294, 1994
16. Bur ME, Perlman C, Edelmann L, et al: p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 98:81-87, 1992
17. Inoue M, Fujita M, Enomoto T, et al: Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 102:665-670, 1994
18. King SA, Adas AA, LiVolsi VA, et al: Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 75:2700-2705, 1995
19. Sherman ME, Bur ME, Kurman RJ: P53 in endometrial cancer and its putative precursors. HUM PATHOL 26:1268-1274, 1995
20. Okamoto A, Sameshima Y, Yamada Y, et al: Allelic loss on chromosome 17 p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 51:5632-5636, 1991
21. Risinger H, Dent GA, Ingar-Trowbridge D, et al: P53 gene mutations in human endometrial carcinoma. Mol Carcinog 5:250-253, 1992
22. Honda T, Kato H, Imamura T, et al: Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 53:963-967, 1993
23. Kohler MF, Berchuk A, Davidoff AM: Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627, 1992
24. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, Wiley, 1980
25. Koshiyama M, Konishi I, Wang D, et al: Immunohistochemical analysis of p53 protein overexpression in endometrial carcinomas: Inverse correlation with sex steroid receptor status. Virchows Arch [A] 423:265-272, 1993
26. Kastan MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and gadd 45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992
27. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
28. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
29. Shaulsky G, Goldfinger M, Peled A, et al: Involvement of wild-type p53 in pre B-cell differentaiation in vitro. Proc Natl Acad Sci U S A 88:8982-8986, 1991
30. De Oca Luna R, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206, 1995
31. Jones SN, Roe AE, Donehower LA, et al: Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378:206-208, 1995
32. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF 1, a potential mediator of p53 suppression. Cell 75:817-825, 1993
33. Xiong Y, Hannon GJ, Zhang H, et al: P21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
34. Seto E, Ushev A, Zambetti GP, et al: Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89:12028-12032, 1992
35. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327, 1993
36. Mietz JA, Unger T, Huibregtse JM, et al: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013-5020, 1992
37. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
38. Bosari A, Viale G, Radaelli U, et al: p53 accumulation in ovarian carcinomas and its prognostic implications. HUM PATHOL 24:1175-1179, 1993
39. Levesque MA, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:132-1338, 1995
40. Klemi P-J, Pylkkänen L, Kiilholma P, et al: P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208, 1995
41. White PF, Merino MJ, Barwick KW: Serous surface papillary carcinoma of the ovary: A clinical, pathologic, ultrastructural and immunohistochemical study of 11 cases. Pathol Annu 20:403-418, 1985
42. Rothacker D, Möbius G: Varieties of serous surface papillary carcinoma of the peritoneum in Northern Germany: A thirty year autopsy study. Int J Gynecol Pathol 14:310-318, 1995
43. Gooneratne S, Sassone M, Blaustein A, et al: Serous surface papillary carcinoma of the ovary: A clinicopathologic study of 16 cases. Int J Gynecol Pathol 1:258-269, 1982
44. Mills SE, Andersen WA, Fechner RE, et al: Serous surface papillary carcinoma: A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol 12:827-834, 1988
45. Truong LD, Maccato ML, Awalt H, et al: Serous surface carcinoma of the peitoneum: A clinicopathologic study of 22 cases. HUM PATHOL 21:99-110, 1990
46. Ransom D, Patel S, Keeny G, et al: Papillary serous carcinoma of the peritoneum: Review of 33 cases treated with platin-based chemotherapy. Cancer 66:1091-1094, 1990
47. Lauchlan S: The secondary Müllerian system. Obstet Gynecol Surv 27:133-145, 1972